The pricing dynamics of biosimilars, depends on the type of biosimilar, its indication and the chann...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreOn 28th September there was a two-hour public hearing on the GKV Financial Stabilisation Act. There ...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe legislation is an updated, smaller version of The Build Back Better Act (BBBA) which the US Sena...
Read moreAccording to the TLV, “The prices of medicines that have been on the market between 5 and 15 years...
Read moreLegislation published in the Journal Officiel on 14th April 2022 establishes a first list of similar...
Read morePatents are usually only valid for around 20 years however, as patenting occurs early in the R&D pro...
Read moreBiosimilars could be launching a lot earlier in the UK than the EU thanks to new guidance, improved ...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read more